MANAGEMENT OF ENDOCRINE DISEASE: Present and future perspectives for medical therapy of nonfunctioning pituitary

Yona Greenman1

  • 1Institute of Endocrinology, Metabolism and Hypertension, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Insights

For nonfunctioning pituitary adenomas (NFPA) after surgery, treatment options like watchful waiting, radiation, or medication lack comparative studies. This review explores off-label medication use for NFPA management.

Area of Science:

  • Endocrinology
  • Neurosurgery
  • Oncology

Background:

  • Clinically nonfunctioning pituitary adenomas (NFPA) present treatment challenges post-surgery.
  • Evidence comparing watchful waiting, irradiation, and medical therapy for NFPA is limited.
  • No specific medical therapies are currently FDA-approved for NFPA treatment.

Purpose of the Study:

  • To review current data on medications approved for secreting pituitary adenomas, used off-label for NFPA.
  • To discuss treatment optimization strategies for NFPA.
  • To explore potential future therapeutic approaches for NFPA.

Main Methods:

  • Literature review of studies on pituitary adenoma treatments.
  • Analysis of off-label medication use in NFPA management.
  • Synthesis of data on approved drugs for secreting adenomas applied to NFPA.

Main Results:

  • Accumulating data suggests potential off-label efficacy of certain medications in NFPA.
  • Current treatment strategies for post-surgical NFPA lack robust comparative evidence.
  • Further research is needed to establish approved medical therapies for NFPA.

Conclusions:

  • Off-label use of medications approved for secreting pituitary adenomas warrants further investigation for NFPA.
  • Optimizing NFPA management requires exploring novel therapeutic avenues.
  • Future research should focus on comparative studies and developing approved NFPA treatments.

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
440
Hormones of the Pituitary Gland01:27

Hormones of the Pituitary Gland

The small, pea-sized pituitary gland is located at the base of the brain. It is crucial in regulating various bodily functions, from growth to reproduction. The gland is divided into the anterior lobe and the posterior lobe. The secretory cell clusters in the pars distalis of the anterior pituitary lobe are controlled by hypothalamic regulators and synthesize six primary hormones.
The most abundantly secreted hormone from the anterior lobe is the growth hormone, which controls overall growth by...
11.0K
The Pituitary Gland01:17

The Pituitary Gland

The pituitary is a small endocrine organ in the sphenoid bone under the hypothalamus. Primarily, the pituitary in adults has two distinct anatomical and functional regions— the anterior and posterior lobes. During human fetal development, a third pituitary gland region called the pars intermedia atrophies and disappears. However, some of its cells migrate and exist adjacent to the anterior pituitary in adults.
11.8K